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Background: The implantation process after embryo transfer depends on the embryo quality and endometrial
receptivity. It is estimated that fifty to seventy-five per cent of pregnancies are lost due to a failure of implantation.
There is evidence that there is an early secretion of human chorionic gonadotrophin before embryo implantation,
and this secretion has been linked to an important function in angiogenesis and the inflammatory response that
promotes the implantation process. Our objective was to determine the effects of intrauterine injection of human
chorionic gonadotropin (hCG) before the embryo transfer in an in vitro fertilisation cycle.
Methods: A prospective randomised study was conducted in Reproductive Medicine Centre PROCREA in Mexico
City. Infertile patients who had a medical indication for in vitro fertilisation were studied. Two groups were included
(n 210); the intervention group received an intrauterine injection of 500 IU of hCG before the embryo transfer
(n 101). The control group (n 109) did not receive hCG. Comparisons were performed using a chi-square test.
Results: The clinical pregnancy rate (CPR) was our principal outcome. The implantation rate was a secondary
outcome. The implantation rate was significantly higher in the hCG group compared to the control group (52.4% vs
35.7%, p 0.014). The clinical pregnancy rate was also significantly higher (50.4 vs 33.0%, p 0.010). No adverse effects
were observed.
Conclusions: The intrauterine injection of hCG before embryo transfer showed a significant increase in the clinical
pregnancy rate. More clinical trials are needed to reproduce these results on this promising intervention. The live
birth rate must be included in subsequent studies.
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Infertility is defined as the failure to conceive after 12
months or more of regular intercourse without contracep-
tion. Epidemiological studies have shown that 80% of the
couples had conceived during that period. It is estimated
that 15% of the couples are infertile in developed countries
[1]. There has not been changes in prevalence; never-
theless, there has been reported a substantial increase in* Correspondence: alvaro2304@hotmail.com
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distribution, and reproduction in any mediumdemand for the treatments [2]. In Vitro Fertilisation (IVF)
is a highly complex technique that involves the use of
standardised protocols for a controlled ovarian stimula-
tion, oocyte retrieval under ultrasound guidance, fertilisa-
tion of gametes in the laboratory, embryo culturing and
embryo transfer [2]. The American Society for Repro-
ductive Medicine (ASRM) and the Society for Assisted
Reproductive Technology Registry (SART) report annu-
ally the live birth rates. For in vitro fertilisation cycles,
the success rate reported is 40.1% in women less than
35 years to 20.6% in women in the 41–42 year range [3].
The implantation process after the embryo transfertral Ltd. This is an Open Access article distributed under the terms of the
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ceptivity. It is estimated that approximately 50% to 75% of
lost pregnancies are due to a failure of implantation [4].
Human chorionic gonadotropin (hCG) is a heterodi-
meric placental glycoprotein hormone that is required to
maintain pregnancy. The hCG is initially produced by
the blastocyst 6–8 days after fertilisation [5,6]. There is
evidence of an early secretion of human chorionic go-
nadotropin by embryos of primates before implantation.
Different mechanisms have been described in which
hCG can regulate implantation. An in vitro study dem-
onstrated that hCG is a potent attractor of inflammatory
cells, such as neutrophils, monocytes, and lymphocytes
[7]. The hCG directly regulates endothelial cell responsive-
ness to interleukin 1 and amplifies the cytokine-mediated
effect on cell proliferation, migration and release of angio-
genic factors [8]. Embryo implantation requires an exten-
sive angiogenesis at the maternal-fetal interface. The hCG
can modulate the receptivity of the endometrial stromal
cells to interleukin-1 by upregulating its receptor (IL1R)
during the implantation window. This function has an im-
pact on angiogenesis, which is a pathway by which embry-
onic growth is promoted [9]. Berndt et al. reported that
hCG displayed a potent angiogenic effect through receptor
activation of transforming growth factor beta (TGF-β) in
endothelial cells, which is a key role in placental develop-
ment [10]. The control of complementary activation in the
embryo environment has been demonstrated to be critical
for embryo survival. Palomino et al. evaluated the expres-
sion of complementary proteins in response to the hCG.
They found an increase in the C3 protein mRNA levels in
stromal cells and an increase in the decay-accelerating
factor in epithelial cells of an endometrial biopsy culture
of infertile women during the implantation window
[11]. Litch et al. developed an intrauterine microdialy-
sis device to measure paracrine mediators. After the
administration of 500 UI of hCG, they found a signifi-
cant inhibition of intrauterine insulin-like growth fac-
tor binding protein 1 (IGFBP-1) and the macrophage
colony-stimulating factor (M-CSF), while leukemia in-
hibitory factor (LIF), the vascular endothelial growth
factor (VEGF) and the matrix metallopeptidase 9 (MMP-9)
were significantly stimulated. These multiple effects ap-
pear to precede the classical endocrine role of the hCG
and could be directly involved in the regulation of embryo
implantation [12].
These mechanisms have been used to design clinical
studies to assess clinical outcomes upon implantation.
Xiao-Yan et al. measured human embryonic human chori-
onic gonadotropin in embryo culture media that was used
during in vitro fertilisation (IVF) cycles, and they found a
positive correlation between the beta-hCG concentration
and the implantation rate, which indicates that the hCG
that is secreted by embryos could be used as a biomarkerfor embryo selection in IVF cycles [13]. Mansour et al. re-
ported the first time use of an intrauterine injection of
hCG before the embryo transfers, and they found a signifi-
cant improvement in the pregnancy rates of the IVF cycles
[14]. These improvements could be explained by various
changes that are produced in the endometrium, which
is where human chorionic gonadotropin has an effect
on implantation [5-12].
Our objective was to reproduce and confirm the benefits
to the clinical effects of intrauterine injection of hCG
before embryo transfer on the pregnancy rates in the
IVF cycles at our reproductive centre.
Methods
This study was a prospective observational study that was
approved by the internal board and ethical committee. A
total of 210 infertile women under the age of 40 who had
an indication for an IVF/ICSI cycle were enrolled in the
study. The exclusion criterion was azoospermia. The study
subjects were recruited voluntarily. A simple randomisa-
tion sample and assignment was generated in a computer-
based program. All of the patients were counselled, and
a written informed consent was obtained from all of the
participants in this study. The screening process for en-
rolment was conducted during scheduled medical ap-
pointments in the PROCREA reproductive centre, and the
patients were followed until a pregnancy test; if the preg-
nancy test was positive, then the pregnancy outcomes
were followed. The data collection was prolective. We ob-
served two groups; one group (n 101) was injected with
500 UI of intrauterine hCG before embryo transfer. The
second group (n 109) did not receive the administration
of hCG. The ovarian stimulation regimen chosen was
an uncontrolled variable because the regimen chosen
was indicated based on individual patient characteris-
tics. Consecutive patients were assigned with simple
randomisation. The preparation of the intrauterine in-
jection of hCG that is described by Mansour’s technique
consisted of adding 500 UI of hCG (Choragon, Ferring
Pharmaceuticals) to 1 mL of culture media (G2, Vitrolife).
Our dilution was prepared to obtain a dose of 500 UI of
hCG with the lowest level of medium. The hCG for intra-
uterine injection was prepared by adding 0.2 mL of tissue
culture media (G2) to one vial that contained 5,000 IU of
hCG. Fecundation was made with conventional in vitro
fertilisation or with intracytoplasmic sperm injection ac-
cording to medical indication. Fresh or vitrified embryos
were used. The embryo transfers were performed upon
cleavage status (day 3). ASRM guidelines for the number
of embryos to be transferred in the in vitro fertilisation
cycles were used.
At the time of the embryo transfer, the patients in both
groups were put in the lithotomy position. The embryo
transfers were performed by 4 medical doctors who






n 109 n 101
Age in years (mean _ SD, range) 7.3 ± 4.0 36.4 ± 4.5 .151
Body mass index
(mean _ SD, range)
26.9 ± 2.9 27.1 ± 2.7 .572
Infertility duration years
(mean _ SD, range)
3.5 ± 1.6 3.3 ± 1.6 .578
Previous IVF cycles 32 (29.3%) 28 (27.7%) .974
Number of Oocytes retrieved
(mean _ SD, range)
9.6 ± 7.3 8.9 ± 5.0 .483
Number of Fertilised oocytes
(mean _ SD, range)
6.6 ± 3.6 6.3 ± 3.3 .594
Infertility types
Female 32 (29.3%) 28 (27.7%)
Male 22 (20.1%) 19 (18.8%)
Mixed 42 (38.5%) 44 (43.5%)
Idiopathic 13 (11.9%) 10 (9.9%)
Technique
IVF 67 (61.5%) 53 (52.5%)
ICSI 37 (33.9%) 39 (38.6%)
PICSI 5 (4.6%) 9 (8.9%)
Types of embryos
Fresh embryos from non-donor 43 (39.4%) 53 (52.5%)
Thawed embryos from non-donor 30 (27.5%) 25 (24.8%)
Donor fresh embryos 29 (26.6%) 17 (16.8%)
Donor thawed embryos 4 (3.7%) 1 (1.0%)
Thawed oocytes from non-donor 3 (2.8%) 5 (5.0%)
Fertilisation rate per retrieved
oocytes
74.8% ± 19.2 75.1% ± 18.9 .931
Embryos transferred
(mean _ SD, range)
2.1 ± 0.6 2.1 ± 0.5 .469
ICSI intra citoplasmic sperm injection. IVF In vitro fertilisation. PICSI
physiological ICSI.
Santibañez et al. Reproductive Biology and Endocrinology 2014, 12:9 Page 3 of 5
http://www.rbej.com/content/12/1/9specialised in Human Reproduction Biology and were cer-
tified by the Mexican Board of Gynecology and Obstetrics
and Reproductive Endocrinology. The transfer was guided
by an abdominal ultrasound with a full bladder. The cervix
was visualised with a vaginal speculum, and then, it was
washed with embryo culture medium. Soft catheters were
used for embryo transfer (Soft-Pass™ Embryo Transfer
Catheter Set, Cook Medical). The soft catheter was
charged with 20 μL of embryo culture medium that con-
tained hCG, and the tip of the catheter was placed 15 mm
to the fundal limit of the uterine cavity. The embryo cul-
ture medium with the hCG preparation included was
injected, and the catheter remained for four minutes in-
side the cavity. Finally, the previously loaded embryos
were transferred. In the control group, the same culture
media for embryos was used for the transfers but without
adding hCG, and it remained for 4 minutes. The preg-
nancy test with biochemical hCG was performed 12 days
after the embryo transfer. If the test was positive, then a
transvaginal ultrasound was performed 2 and 4 weeks
later, to search for signs of pregnancy, such as the pres-
ence of a gestational sac, embryo and fetal heart rate.
PROCREA is only a referral centre for reproductive prob-
lems. Once a viable pregnancy is confirmed, the patient
returns with their gynaecologist for planning their ante-
natal care.
The biochemical pregnancy was defined as positive from
quantitative values of a serum test of β human chorionic
gonadotropin according to standard values that are used
in the laboratory. The clinical pregnancy rate was defined
as a viable pregnancy when there is evidence of a gesta-
tional sac, embryo and fetal heart rate at the time of ultra-
sound evaluation.
Both clínical and biochemical pregnancies are the
principal variables that we used when attempting to
show the benefits of adding hCG to an altered embryo
secretion and damaged endometrium from IVF cycles.
The sample size was calculated to compare two propor-
tions. Clinical pregnancy rates of 35% among women in
IVF cycles were taken from ASRM reports. We expected
to detect an 18% increase in the clinical pregnancy rate,
which is 3% higher than the outcomes published by
Mansour and Cols. A unilateral test was calculated, and
93 women per group were necessary to obtain a power
of 80% at a significance level of 0.05. We used SPSS
version 19.0 (IBM) to perform the statistical analysis.
We characterised sociodemographic variables with de-
scriptive statistics, using the mean with the standard
deviation for the quantitative variables and proportions
for the qualitative variables. The student’s t-test and
Mann–Whitney, where appropriate, were used. For cat-
egorical data, the absolute and relative frequencies were
determined, and the relative risks with 95% confidence
intervals for the proportions were calculated. The Chi-square test and Yates’s correction was used to compare
differences in the proportions of both groups. A p < .05
was considered to be statistically significant, to represent
significant associations.
Results
A total of 210 patients were enrolled from August 2011
through November 2012. Table 1 summarises the baseline
characteristics of the patients. The intervention group had
a patient median age of 36 years, which is one year less
than the control group, but no statistically significant dif-
ferences were found between the groups in terms of the
baseline characteristics. IVF with fresh embryos from non-
donors represented more than 50% of the patients. Almost
3 out of 10 patients had a previous IVF failed cycle. The
fertilisation rate per retrieved oocyte and the number of
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creases in the implantation and clinical pregnancy rates in
the intervention group were statistically significant with a
15% increase in the rates.
The biochemical pregnancy rate has a relative risk of
1.46, and the clinical pregnancy rate has a relative risk of
1.52. Both of the relative risks calculated have 95% con-
fidence intervals, with statistical significance in the size
effect, as we describe in Table 2.
Discussion
In this study, we confirmed the benefit of intrauterine
injection of 500 UI hCG before embryo transfer. The
methodology of the study is not the best design for clin-
ical trials to evaluate clinical interventions; however, the
evidence has been shown for outcomes in which the
clinical pregnancy rate and implantation rate increased
significantly in patients in the intervention group. These
procedures could benefit all of the patient candidates for
IVF/ICSI cycles. The benefit of an early hCG secretion
on the embryo before its implantation has been shown
[5,6,8-12]. Previous studies have shown that there is a
key role for hCG in regulating the inflammatory response
and angiogenesis during embryo implantation [12], and
an altered damaged endometrial receptivity by the IVF
treatments can be overcome by injecting hCG prior to
the embryo transfers.
Xiao-Yan et al. showed that embryos in IVF cycles that
have a higher secretion of hCG in their culture media
have a positive correlation with the implantation rate
[13]. We hypothesised that there is an unknown cause
that could affect these secretory functions on embryos in
the laboratory during the IVF process. Unfortunately,
our observation is limited to between 7 and 9 weeks of
gestation, which is the time when our team evaluates the
viability of the pregnancy through ultrasound. However,
miscarriages appear to not be increased in the interven-
tion group before this time, as we describe in Table 3.
This study included patients with a history of recurrent
miscarriage and implantation failure. This finding is in
contrast with a previous study performed by Mansour
et al. in which the first-time IVF patients were enrolledTable 2 Human chorionic gonadotropin (hCG) injected
during embryo transfer compared to no injection for
















51/101 36/109 1.52 1.09 to 2.12
p 0.01
n outcome; N number of participants.[14]. Selection biases that could affect our internal valid-
ation are variables such as age, which were not controlled.
The limit was that all patients had to be under 40 years
old. The ovarian stimulation protocols were different be-
tween the patients according to their particular character-
istics. The embryo transfer technique was standardised.
The procedure was performed by 4 different operators,
and this number of operators could affect our results be-
cause it has been demonstrated that embryo transfer tech-
niques differ between operators. Our study also included
thawed embryo transfers, in which the benefits of hCG
injection were also shown in this group of patients. We
did not find complications such as embryo retention in
catheters or ectopic pregnancies.
The original methodology was designed to analyse the
reproducibility of the results published by Mansour and
Cols, which is important given that this study showed sig-
nificant effects on the pregnancy rates [14]. Our results
are similar to those previously reported. One difference to
emphasise is that our population group included patients
with previous failed IVF cycles and thawed embryos. We
hypothesised that early secretion of hCG from the embryo
would be decreased before its implantation. This reduc-
tion could be for an unknown cause in relation to the
laboratory fertilisation or vitrification process. Clinical
pregnancy rates in thawed embryo transfers were not
our primary outcome, and the statistical analyses were
not designed for this approach; however, we observed an
improvement in the clinical pregnancy rate, even though
the global clinical pregnancy rates are reported to be lower
in comparison with reports on fresh embryos.
The reason that we included these thawed embryos is
because we hypothesised that the production of hCG by
thawed embryos is decreased prior to the implantation
process, which is, for some reason, related to the vitrifica-
tion process. This group of thawed embryos also had ben-
efits in terms of clinical and biochemical pregnancies that
resulted from adding the hCG. Because of these results
and the previous findings about there being a benefit to
endometrium angiogenesis and the inflammatory re-
sponse, both mechanisms reflect the effects of hCG dir-
ectly in the endometrium instead of having an autocrine
effect on human embryos. More studies with a specific
design, such as independent comparisons of fresh and
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results in this specific group of patients.
PROCREA is only a referral centre for reproductive
problems, and this aspect is a weakness of our study because
the follow-up and control of the patients is not possible
once the patients return to their gynaecologist for planning
their antenatal care. The ultrasound was performed 2–
4 weeks after the initial positive serum beta-hCG level. In
such cases, the gestational age ranges were 6 to 9 weeks.
The intrauterine injection of hCG before the embryo
transfer is a simple procedure. This method does not re-
quire complex training and does not consume additional
time for the embryologist and clinical staff. No special
equipment is necessary for the dilution and preparation of
the hCG, and it is not expensive. The intervention offers a
benefit to a large heterogeneous group of patients, includ-
ing those with thawed embryo transfers, which currently
represents one third of the live birth rate according to the
reports of ASRM/SART [3]. These interventions could be
replicated by all IVF units without great effort and could
be considered to be without major risk.
Conclusions
The intrauterine injection of hCG before embryo transfer
showed a significant increase in the clinical pregnancy
rate. More clinical trials are needed to reproduce these
results for this promising intervention. The live birth
rate must be included in subsequent studies.
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